FDA's long-term vacancy
One potential temporary leader is Sara Brenner, who held the acting title in early 2025 before departing the agency earlier this year to work as a senior counselor for public health at HHS.
- that the user-fee programs pose an “incredible conflict of interest.” “If we’re going to regulate a very, very significant industry, it might be a good idea not to have the industry paying for their regulation,” Sanders told reporters on Wednesday.
- If the user-fee programs are not renewed, Congress would have to come up with more than $3.5 billion in taxpayer money to cover the gap.
- The leadership void arrives as Congress takes up industry user fees, a critical source of about half of FDA’s funding.
FDA leaders have urged Congress to empower regulators with new authorities to mandate drug recalls and compel drugmakers to share data on their supply chains.
Bernie Sanders, I-Vt., who will lead the Senate’s health committee next year, told reporters he shares concerns with HHS Secretary Robert F.
- Former FDA officials told me they expect a string of acting commissioners to fill in for the next two years.
- Another name being floated is Karim Mikhail, the FDA’s top regulator of vaccines and biologics.
- Marshall declined to comment on Wednesday on whether he was still under consideration.
- Notable My colleagues and I reported this week that Republicans were looking at Sen.
- Without a permanent agency leader, it’s unclear who would champion these changes.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →